Literature DB >> 14692017

The process for continuous improvement of the TNM classification.

Mary K Gospodarowicz1, Daniel Miller, Patti A Groome, Frederick L Greene, Pamela A Logan, Leslie H Sobin.   

Abstract

The TNM classification is a worldwide benchmark for reporting the extent of malignant disease and is a major prognostic factor in predicting the outcome of patients with cancer. The objectives for cancer staging were defined by the International Union Against Cancer (UICC) TNM Committee almost 50 years ago and are still broadly applicable today. To keep pace with the modern demands of evidence-based practice, the UICC introduced a structured process for introducing changes to the TNM classification. The elements of the TNM process were determined to include the development of unambiguous criteria for the information and documentation required to consider changes in the classification, establishment of a well-defined process for the annual review of relevant literature, formation of site-specific expert panels, and the participation of experts from all over the world in the TNM review process. Communication between the oncology community and those involved in the TNM classification was established as being essential to the success of the process. The process, which was introduced in 2002, will be tested over the next 3-4 years and evaluated. In addition to the formal process, individual initiative, involvement by the national staging committees, and group consensus are required. Furthermore, increased involvement by the experts should improve the understanding and dissemination of the TNM classification.

Entities:  

Mesh:

Year:  2004        PMID: 14692017     DOI: 10.1002/cncr.11898

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  50 in total

1.  Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.

Authors:  Alyson L Mahar; Carolyn Compton; Lisa M McShane; Susan Halabi; Hisao Asamura; Ramon Rami-Porta; Patti A Groome
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

2.  The evolving TNM cancer staging system: an essential component of cancer care.

Authors:  James Brierley
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

3.  M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma.

Authors:  Lujun Shen; Jun Dong; Sheng Li; Yue Wang; Annan Dong; Wanhong Shu; Ming Wu; Changchuan Pan; Yunfei Xia; Peihong Wu
Journal:  Oncologist       Date:  2015-02-06

Review 4.  Lung cancer staging: clinical and radiologic perspectives.

Authors:  Sophie Chheang; Kathleen Brown
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

Review 5.  [New aspects for staging and grading of tumor metastases].

Authors:  C Wittekind
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

6.  The pathologist's role in rectal cancer patient assessments.

Authors:  Joseph E Willis
Journal:  Clin Colon Rectal Surg       Date:  2007-08

7.  Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?

Authors:  Binkui Li; Yunfei Yuan; Guihua Chen; Liru He; Yaqi Zhang; Jinqing Li; Guohui Li; Wan Yee Lau
Journal:  BMC Cancer       Date:  2010-10-07       Impact factor: 4.430

8.  Staging colorectal cancer with the TNM 7(th): the presumption of innocence when applying the M category.

Authors:  Giacomo Puppa; Graeme Poston; Per Jess; Guy F Nash; Kenneth Coenegrachts; Axel Stang
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

9.  An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus.

Authors:  Bas P L Wijnhoven; Khe T C Tran; Adrian Esterman; David I Watson; Hugo W Tilanus
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

Review 10.  APC and its modifiers in colon cancer.

Authors:  Lawrence N Kwong; William F Dove
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.